News

In collaboration with four prestigious neurologists, Pivotal has begun screening patients for the Phase I research effort, which is expected to have major implications for the treatment of

The study randomized 61 patients into three treatment groups (two dose levels of Topical PTH (1-34) and one vehicle only group) for an eight-week treatment period at four

The new MAX technology provides tremendous power and performance optimization advantages for our customers’ products, regardless of the complexity of their designs, said Charlie Zhi, chief executive officer

Under the terms of the license, Proteome Sciences will manufacture its patented TMTA reagents exclusively for Thermo Fisher Scientific, which will market and sell them worldwide through the

The prospective non-inferiority study is designed to evaluate the safety and efficacy of EDAP’s Ablatherm-HIFU system versus Cryotherapy for the treatment of low-risk, localized prostate cancer. The clinical

In this initial proof of concept study, 39 subjects diagnosed with obstructive sleep apnea (OSA) received placebo, a single agent or one of two doses of BGC20-0166 daily

Through a tender offer by its wholly owned subsidiary, Packer Acquisition (the Purchase), Opto Circuits had previously acquired approximately 92.8% of the outstanding shares of Criticare common stock

The FDA will review any submission the company makes to determine whether it meets the requirements for filing. There can be no assurance that the FDA will file

According to the agreement, Laureate will produce Alopexx’s mAb F598 antibody under cGMP conditions. This antibody is planned for use in clinical trials, and later for commercial production